This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AMN or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
AMN vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
AMN or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
GoodRx Holdings, Inc. (GDRX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of -10% and 1.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
GoodRx Holdings, Inc. (GDRX) Surges 5.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MODV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. GDRX: Which Stock Is the Better Value Option?
GoodRx Holdings, Inc. (GDRX) Q3 Earnings Top Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 12.50% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AMN vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Earnings Preview: GoodRx Holdings, Inc. (GDRX) Q3 Earnings Expected to Decline
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
It's Time to Break Up With These 4 Toxic Stocks
by Rimmi Singhi
Identifying toxic stocks and getting rid of them at the right time is the key to guard your portfolio from big losses.
MODV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. GDRX: Which Stock Is the Better Value Option?
MODV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. GDRX: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: GoodRx Holdings, American Well Corp, Accolade, SOC Telemed and Teladoc
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GoodRx Holdings, American Well Corp, Accolade, SOC Telemed and Teladoc
Booming Telehealth Market Lures More IPOs and M&A Deals
by Sapna Bagaria
To make the most of the booming telehealth industry, players are coming up with IPOs and resorting to mergers and acquisitions.
GoodRx (GDRX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
GoodRx' (GDRX) manufacturer solutions offerings continue to grow at a strong rate, registering record bookings over the past months.
Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways
by Zacks Equity Research
Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways
5 Top Medical Services Stocks to Beat COVID-Led Industry Challenges
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Services industry. AVTR, ERFSF, GDRX, AMEH and CMPS are poised to gain.